From Financial Modeling Prep: 2025-04-30 10:04:00

Morgan Stanley downgraded Avantor, Inc. (NYSE:AVTR) to Equal-Weight due to financial concerns. Avantor’s Q1 2025 earnings showed adjusted EPS of 23 cents, but revenues fell to $1.58 billion, missing estimates. Stock dropped 16.6% post-earnings.

Avantor operates in life sciences and advanced technologies, facing competition from companies like Thermo Fisher Scientific. Morgan Stanley downgraded Avantor to Equal-Weight on April 29, 2025, at $12.68 per share. Downgrade reflects financial challenges highlighted in recent earnings report.

Q1 2025 earnings for Avantor showed adjusted EPS of 23 cents, up 4.5% YoY, but GAAP EPS remained flat at 9 cents. Revenues fell to $1.58 billion, down 5.9% YoY, missing estimates by 1.7%. Revenue decline due to foreign currency translation and divestiture of Clinical Services.

Avantor’s stock dropped 16.6% post-earnings, with the Laboratory Solutions segment reporting an 8% decrease in net sales. Bioscience Production segment showed strong growth. AVTR currently priced at $12.73, up 0.28%. Market cap around $8.67 billion, trading volume of 1,650,299 shares on NYSE.



Read more at Financial Modeling Prep:: Avantor, Inc. (NYSE:AVTR) Downgraded by Morgan Sta…